Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul-Aug;154(1-2):18-24.
doi: 10.1016/j.imlet.2013.08.002. Epub 2013 Aug 15.

A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro

Xiaoying Zhu  1 , Kun Tao, Yajuan Li, Shenfeng Li, Lijun Zhang, Dong Wang, Liang Zhong, Wenli Feng
Affiliations

A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro

Xiaoying Zhu et al. Immunol Lett. 2013 Jul-Aug.

Abstract

Antibodies against cell surface antigens of tumor have attracted increasing attention in immunotherapy for tumor diagnosis and treatment. Recently, we constructed a new recombinant immunotoxin for possible clinical application in patients with chronic myeloid leukemia (CML). A functional humanized single chain variable fragment (hscFv) against CML patient cells was previously obtained from an anti-CML cell hybridoma derived monoclonal antibody. By insertion into the bacterial vector pWW20, the hscFv was fused with a deletion mutant of Pseudomonas exotoxin A (ETA'). Then the fusion fragment was inserted into the bacterial vector pET32a(+). After isopropyl β-d-thiogalactoside (IPTG) induction, the 6× His tagged hscFv-ETA' protein was periplasmically expressed and purified by Ni(2+)-NTA column. The characteristics of the recombinant protein were assessed by cell membrane-ELISA, flow cytometry, and toxicity assays in CML cell lines and CML patient cells. The recombinant immunotoxin showed significant toxicity toward the CML cell lines K562 and KU812 as tested by MTT and apoptosis assay. Approximately 37% of leukemia cells of CML patients were driven into apoptosis by hscFv-ETA' as measured by flow cytometric analysis. In conclusion, the hscFv-ETA' is efficacious against CML in vitro, providing the basis for a novel therapeutic strategy for the treatment of CML patients.

Keywords: Chronic myeloid leukemia; Recombinant immunotoxin; Targeting therapy; hscFv.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

MeSH terms